Long-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levels

Basit Öğe Kaydı
dc.authoridAkin, Senay/0000-0001-5729-5944
dc.authoridGURAY, UMIT/0000-0002-6604-2970
dc.contributor.authorAkin, Senay
dc.contributor.authorGucuk-Ipek, Esra
dc.contributor.authorHayta, Umit
dc.contributor.authorGungor, Irem
dc.contributor.authorKubat, Gokhan Burcin
dc.contributor.authorAkin, Yesim
dc.contributor.authorGuray, Umit
dc.date.accessioned2024-09-29T15:51:12Z
dc.date.available2024-09-29T15:51:12Z
dc.date.issued2023
dc.departmentKarabük Üniversitesien_US
dc.description.abstractPurpose Glucocorticoids, which are widely prescribed around the world, cause cardiac remodeling in long-term treatment by triggering insulin resistance and increasing blood pressure. However, its role in cardiac remodeling remains unclear. Galectin-3 (gal-3) is a member of a beta-galactoside-binding animal lectins, upregulated as a result of insulin resistance and in the pressure-overloaded myocardium and regulate cardiac remodeling. We hypothesized that gal-3 may be upregulated in the myocardium with prolonged use of glucocorticoids and associated with cardiac hypertrophy. Methods To examine the involvement of glucocorticoids in gal-3 levels in rat myocardium, sixteen female Wistar Albino rats were assigned to control (C; n= 8) and dexamethasone (Dex; n= 8) groups. Daily dexamethasone was injected subcutaneously for 28 days at a dose of 1 mg.kg(-1). Control animals were injected with the same volume of saline. The body weight and heart weights were determined. Gal-3 levels in myocardium were determined by Western blot. Results Our data shows that dexamethasone administration resulted in significant increase in heart weight (p < 0.05) and HW/BW ratios (p < 0.001) and 28 days of dexamethasone administration with the dose of 1 mg.kg(-1) caused a twofold increase in the gal-3 expression in the left ventricle (p < 0.001). Conclusion The finding of the current study is the first to show that dexamethasone causes an increase in gal-3 levels in myocardium. Our study provides an important step in the development of possible therapeutics by determining that dexamethasone causes an increase in gal-3 levels in the myocardium and raises awareness about the follow-up of patients receiving long-term glucocorticoid therapy.en_US
dc.identifier.doi10.1007/s10557-022-07344-w
dc.identifier.endpage1029en_US
dc.identifier.issn0920-3206
dc.identifier.issn1573-7241
dc.identifier.issue5en_US
dc.identifier.pmid35554772en_US
dc.identifier.scopus2-s2.0-85129843733en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1027en_US
dc.identifier.urihttps://doi.org/10.1007/s10557-022-07344-w
dc.identifier.urihttps://hdl.handle.net/20.500.14619/3929
dc.identifier.volume37en_US
dc.identifier.wosWOS:000795024200001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofCardiovascular Drugs and Therapyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGlucocorticoidsen_US
dc.subjectGalectin-3en_US
dc.subjectCardiac fibrosisen_US
dc.subjectCardiomyocyteen_US
dc.titleLong-term Dexamethasone Treatment Increases Cardiac Galectin-3 Levelsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu